Price: quote on request. Your total cost is quoted in writing per case.
We give you a written timeline estimate for your case before you commit.
Ask about treatment

Alopecia areata: US-approved treatments and how families in the Gulf can access them

A plain guide for families in the Gulf, checked against US FDA labels, US National Institutes of Health information, Gulf drug registers and published research on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Alopecia areata: the short answer

The US FDA has approved three medicines covered on this page for alopecia areata, each for a specific group of patients: Olumiant, Litfulo and Leqselvi. On 17 October 2026, two of them were on the Saudi or Abu Dhabi register, so ask your hospital about local supply first. Where a medicine is not registered, the treating hospital can ask the national regulator to import it for one named patient. Reserve Meds is a digital health company that helps with that process. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Olumiant, Litfulo and Leqselvi.
  • Gulf registers (checked 17 October 2026): see each medicine below.
  • Legal route: local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is alopecia areata?

Alopecia areata is a common disorder that causes hair loss. In most people, hair falls out in small, round patches, leaving coin-sized areas of bare skin, most often on the scalp. Uncommonly, it affects the whole scalp (alopecia totalis) or the whole body (alopecia universalis).[1]

It affects 1 in every 500 to 1,000 people in the United States, and men and women equally. It is the second most common form of hair loss after male-pattern and female-pattern baldness.[1]

The causes are complex and not well understood. Changes in many genes involved in the hair, the skin and the immune system likely play a part, and alopecia areata is considered an autoimmune condition.[1]

Alopecia areata in the Gulf

Dermatologists in the Gulf have published on this condition, including a 2023 Saudi expert consensus on diagnosis and management, a retrospective analysis of epidemiology and treatment patterns in the United Arab Emirates, and a 2025 review of its burden and management with baricitinib in the UAE.[2, 3, 4]

We checked every medicine on this page against the full SFDA drugs list and the Abu Dhabi Department of Health drug code list on 17 October 2026. 2 of 3 were listed in Saudi Arabia and 2 of 3 in Abu Dhabi. The result for each medicine is shown below. A listing does not mean every hospital stocks the medicine, and federal UAE, Kuwait, Qatar, Bahrain and Oman registers were not checked.[5, 6]

US FDA-approved medicines for alopecia areata

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Olumiant (baricitinib)
    US FDA-approved for severe alopecia areata in adults and children 12 years and older. It is a JAK inhibitor tablet.[7]
    Current US label version: 25 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
    Country access guides: Saudi Arabia, UAE, Kuwait, Qatar
  • Litfulo (ritlecitinib)
    US FDA-approved for severe alopecia areata in adults and adolescents 12 years and older. It is a kinase inhibitor capsule.[8]
    Current US label version: 17 June 2026. Gulf registers: Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (DoH drug code list): listed. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]
    Country access guides: Kuwait, Bahrain, Jordan, Turkey, India
  • Leqselvi (deuruxolitinib)
    US FDA-approved for adults with severe alopecia areata. It is a JAK inhibitor tablet.[9]
    Current US label version: 28 September 2026. Gulf registers: Saudi Arabia (SFDA drugs list): not found. Abu Dhabi (DoH drug code list): not found. Checked 17 October 2026. Federal UAE, Kuwait, Qatar, Bahrain and Oman: not checked; we confirm for your country when you ask.[5, 6]

How families in the Gulf can access treatment

If the medicine is listed in your country. Ask your specialist and the hospital about local supply first. A listing does not mean every hospital stocks the medicine, but it is usually the fastest route, and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital confirms.[10, 11] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the medical letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
  • Reports that confirm the diagnosis, such as genetic, pathology, imaging or laboratory results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate for your case before you commit. The regulator, the hospital or treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for alopecia areata

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for alopecia areata?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Olumiant, Litfulo and Leqselvi. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Olumiant available in Saudi Arabia or the UAE?

We checked on 17 October 2026. Saudi Arabia (SFDA drugs list): listed. Abu Dhabi (Department of Health drug code list): listed. A listing in Abu Dhabi does not show federal UAE status, which we could not verify. Your hospital confirms current supply.

How can a family in the Gulf get Olumiant?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Which US-approved medicines treat severe alopecia areata?

Olumiant and Litfulo are approved for severe alopecia areata from age 12, and Leqselvi for adults. All three are oral JAK or kinase inhibitors, and the labels carry safety warnings your dermatologist will explain.

Sources for the condition-specific answers: [7, 8, 9]

Sources

Accessed and checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital confirms the current position before anything is filed.

  1. MedlinePlus Genetics (US National Library of Medicine): Alopecia areata
  2. Fatani MIA, et al. Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023). Dermatol Ther (Heidelb). 2023 (PubMed 37558830)
  3. Hammadi AA, et al. A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database. J Dermatol. 2024 (PubMed 39051178)
  4. Dayem HA, et al. The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review. Dermatol Ther (Heidelb). 2025 (PubMed 41023528)
  5. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  6. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  7. DailyMed: OLUMIANT (baricitinib) US prescribing information, label version 25 September 2026
  8. DailyMed: LITFULO (ritlecitinib) US prescribing information, label version 17 June 2026
  9. DailyMed: LEQSELVI (deuruxolitinib) US prescribing information, label version 28 September 2026
  10. SFDA: Special Access Program (SAP) guidance, version 1.0
  11. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp